Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Immune Outcomes to Neonatal Antigen Delivery in the Intestine

Award Number: R01DK134366
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/15/2023
PERIOD OF PERFORMANCE END DATE: 04/30/2028

Group Awards By:

View Award Description

Immune Outcomes to Neonatal Antigen Delivery in the Intestine - PROJECT ABSTRACT The intestinal lumen contains a plethora of proteins from the diet and microbiota that require tolerogenic responses. If tolerance is not properly mounted against these innocuous proteins the mucosal immune system constantly encounters, individuals become progressively at-risk for inflammatory disorders including food allergies or inflammatory bowel diseases. As these disorders increase in incidence, particularly within the pediatric population, understanding how the immune system encounters luminal antigens during early life must be thoroughly explored for the prevention and treatment of these disorders. Currently, exclusive breastfeeding is the recommended dietary practice for infants through the first three months, followed by complementary breastfeeding with introduction of solid foods. Yet the world health organization estimates only 30% of infants globally are exclusively breastfed in the first three months, and alternative diets ranging from infant formula to goat’s milk are used for a variety of reasons. Breastfeeding is significantly associated with decreased risk of food allergy and IBD, and a number of beneficial components of breast milk have been identified. We have previously shown epidermal growth factor (EGF) is highly concentrated in breastmilk, particularly early in lactation. Immediately following delivery, EGF inhibits antigen delivery within the neonates intestine, and a lack of dietary EGF is associated with increased intestinal permeability. As the infant ages, EGF in breastmilk decreases allowing antigen delivery to occur and FoxP3+ regulatory T cells develop in response to orally derived antigens during this time. Thus, maternal EGF regulates antigen delivery until a time when the infant is prepared to develop tolerogenic responses to encountered antigen. Our preliminary data shows decreased dietary EGF or disrupting the Epidermal Growth Factor Receptor within intestinal cells of the neonate resulted in early antigen delivery, decreased FoxP3+ regulatory T cells at the time of weaning, and an increased predisposition to intestinal inflammation in a model of colitis. Interestingly, while FoxP3+ regulatory T cell differentiation was initiated in response to early antigen delivery, these cells eventually lost FoxP3 expression but remained in the intestine, becoming effector cells. Antigen delivery was also associated with an increase in CX3CR1+ F4/80+ antigen presenting cells, however the role neonatal antigen presenting cells downstream of antigen delivery remains unknown. These data suggest early antigen delivery in the absence of maternal EGF regulation disrupts oral tolerance during early life. Here we will 1) determine the effect of neonatal antigen delivery on antigen presenting cells in the colon and 2) determine the mechanism through which neonatal antigen delivery abrogates regulatory T cells. This work has important implication in why antigen delivery during early life is regulated by breast milk, and the consequences of early antigen delivery in the absence of maternal regulation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $388,504 )
2026	2026	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	4/9/2026	NON-COMPETING CONTINUATION	$388,504
														Subtotal = $388,504

Issue Date FY: 2025 ( Subtotal = $388,504 )
2025	2025	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	5/7/2025	NON-COMPETING CONTINUATION	$388,504
														Subtotal = $388,504

Issue Date FY: 2024 ( Subtotal = $372,964 )
2024	2024	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	5/7/2024	NON-COMPETING CONTINUATION	$372,964
														Subtotal = $372,964

Issue Date FY: 2023 ( Subtotal = $388,504 )
2023	2023	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	7/10/2023	NEW	$388,504
														Subtotal = $388,504

Grand Total All Awards = $1,538,476

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Immune Outcomes to Neonatal Antigen Delivery in the Intestine

Award Number: R01DK134366

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/15/2023

PERIOD OF PERFORMANCE END DATE: 04/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer